Emergent Biosolutions
EBS
126 hedge funds and large institutions have $451M invested in Emergent Biosolutions in 2013 Q3 according to their latest regulatory filings, with 19 funds opening new positions, 62 increasing their positions, 29 reducing their positions, and 5 closing their positions.
280% more first-time investments, than exits
New positions opened: 19 | Existing positions closed: 5
114% more repeat investments, than reductions
Existing positions increased: 62 | Existing positions reduced: 29
100% more funds holding in top 10
Funds holding in top 10: 1 → 2 (+1)
40% more capital invested
Capital invested by funds: $323M → $451M (+$128M)
12% more funds holding
Funds holding: 113 → 126 (+13)
1.92% more ownership
Funds ownership: 64.42% → 66.34% (+1.9%)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
SCA
SAC Capital Advisors
Stamford,
Connecticut
|
+$5.77M |
| 2 |
Manulife (Manufacturers Life Insurance)
Canada,
Ontario, Canada
|
+$3.68M |
| 3 |
BFA
BlackRock Fund Advisors
San Francisco,
California
|
+$3.43M |
| 4 |
Goldman Sachs
New York
|
+$2.13M |
| 5 |
NI
Numeric Investors
Boston,
Massachusetts
|
+$1.72M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Millennium Management
New York
|
-$4.13M |
| 2 |
BNP Paribas Asset Management
Paris,
France
|
-$2.36M |
| 3 |
Renaissance Technologies
New York
|
-$2.25M |
| 4 |
Bank of New York Mellon
New York
|
-$1.79M |
| 5 |
State Street
Boston,
Massachusetts
|
-$1.57M |
| Name | Holding | Trade Value |
Shares Change |
Change in Stake |
|
|---|---|---|---|---|---|
|
126
BNP Paribas Asset Management
Paris,
France
| – | -$2.36M | -163,497 | Closed |
|
|
FNYS
127
First New York Securities
New York
| – | -$797K | -55,300 | Closed |
|
|
RA
128
Royce & Associates
New York
| – | -$438K | -30,386 | Closed |
|
129
Tudor Investment Corp
Stamford,
Connecticut
| – | -$316K | -21,900 | Closed |
|
|
TRCT
130
Tower Research Capital (TRC)
New York
| – | -$4K | -300 | Closed |
|
EBS Hedge Fund Activity: Q3 2013 in Review
126 of the 3,084 institutional investors tracked by Wall St. Rank reported a position in Emergent Biosolutions (EBS) for Q3 2013, worth a combined $451M — up 40% from $323M a quarter earlier.
Buyers outnumbered sellers: 19 funds opened new EBS positions and 5 closed out — a net gain of 14 holders — while 62 added to existing stakes and 29 trimmed.
The largest buyer was SAC Capital Advisors, adding an estimated $5.77M. The largest seller was Millennium Management, cutting an estimated $4.13M.
- 126 institutional investors held Emergent Biosolutions (EBS) as of Q3 2013, up from 113 in Q2 2013.
- Funds reported $451M of Emergent Biosolutions stock for Q3 2013, up 40% quarter-over-quarter.
- 19 funds opened new Emergent Biosolutions positions in Q3 2013 and 5 closed out, a net change of +14 holders.
- The largest Emergent Biosolutions buyer in Q3 2013 was SAC Capital Advisors, an estimated $5.77M added.
- The largest Emergent Biosolutions seller in Q3 2013 was Millennium Management, an estimated $4.13M sold.
Based on aggregated 13F filings for Q3 2013.